Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma
Status:
Terminated
Trial end date:
2019-06-12
Target enrollment:
Participant gender:
Summary
Phase 1b: To evaluate safety and tolerability and determine a recommended phase 2 dose for
TRC105 when added to standard dose axitinib in patients with advanced renal cell carcinoma.
Phase 2: To estimate the PFS of patients with advanced or metastatic RCC by RECIST 1.1
criteria in patients treated with axitinib and TRC105 compared to those treated with axitinib
alone, following failure of one prior VEGF TKI